Market: NASD |
Currency: USD
Address: 5857 Owens Avenue
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
📈 Qualigen Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
10-25%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2024 |
- |
$0.020000 |
- |
2024-11-05 |
- |
Stock split |
|
Total Amount for 2024: $0.020000 |
| 2022 |
- |
$0.100000 |
- |
2022-11-23 |
- |
Stock split |
|
Total Amount for 2022: $0.100000 |
| 2020 |
- |
$0.040000 |
- |
2020-05-26 |
- |
Stock split |
|
Total Amount for 2020: $0.040000 |
| 2018 |
- |
$0.100000 |
- |
2018-03-23 |
- |
Stock split |
|
Total Amount for 2018: $0.100000 |
📅 Earnings & EPS History for Qualigen Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2024-04-08 | -7.71 |
| 2023-11-14 | -36 |
| 2023-08-14 | -34.5 |
| 2023-05-15 | -39 |
| 2023-05-02 | -23.19 |
| 2022-11-14 | -50 |
| 2022-08-15 | -55 |
| 2022-05-13 | -60 |
| 2022-03-31 | -72.2 |
| 2021-11-15 | -82.7 |
| 2021-08-16 | -90 |
| 2021-05-14 | -65 |
📰 Related News & Research
No related articles found for "qualigen therapeutics".
